Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
Purpose of this study was to evaluate prognostic impact of rare variants of urothelial bladder cancer (BC) after treatment with combined radiochemotherapy (RCT). To this end tumour tissue of 238 patients with urothelial carcinoma (UC) treated with transurethral resection of the bladder (TUR-B) and R...
| Publicado en: | Virchows Archiv: European Journal of Pathology Vol. 469; no. 3; pp. 339 - 345 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117790544&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 117790544 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09456317 O1Z jtl: Virchows Archiv: European Journal of Pathology issn: 09456317 maglogo: N pubinfo: dt: Sep2016 vid: 469 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 117790544 117790544 NLM27392930 117790544 10.1007/s00428-016-1986-x NLM27392930 117790544 ppf: 339 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. aug: au: Bertz, Simone Wach, S. Taubert, H. Merten, R. Krause, F. Schick, S. Ott, O. Weigert, E. Dworak, O. Rödel, C. Fietkau, R. Wullich, B. Keck, B. Hartmann, A. Krause, F S Ott, O J Rödel, C affil: Department of Pathology , University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg , Krankenhausstraße 8-10 91054 Erlangen Germany sug: subj: Urologic Neoplasms Diagnosis Carcinoma, Transitional Cell Pathology Carcinoma, Transitional Cell Diagnosis Urologic Neoplasms Pathology Carcinoma, Papillary Pathology Carcinoma, Papillary Therapy Adult Epithelium Pathology Urologic Neoplasms Therapy Aged Male Prognosis Female Aged, 80 and Over Carcinoma, Papillary Diagnosis Middle Age Human Adult: 19-44 years Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Male Female ab: Purpose of this study was to evaluate prognostic impact of rare variants of urothelial bladder cancer (BC) after treatment with combined radiochemotherapy (RCT). To this end tumour tissue of 238 patients with urothelial carcinoma (UC) treated with transurethral resection of the bladder (TUR-B) and RCT with curative intent was collected. Histomorphological analysis included re-evaluation and semi-quantitative assessment of rare UC subtypes. Additionally, human epidermal growth factor receptor 2 (HER2) chromogenic in situ hybridisation (CISH) was performed in tumours with a micropapillary component exceeding 30 %. Long-term follow-up was available for 200 patients (range 3-282 months). Variant UC histology was found in 45 of 238 tumours, most frequently micropapillary UC (N = 17) including cases with a small fraction of tumour with micropapillary morphology. The mere presence of micropapillary morphology did not affect prognosis. In tumours with extensive (≥30 %) micropapillary morphology (N = 8) Kaplan-Meier analysis revealed significantly worse cancer specific survival (CSS) (P = 0.002) compared to conventional UC (mean survival times 97 months and 229 months, respectively). Univariate Cox regression analysis of cases with ≥30 % micropapillary morphology revealed a hazard ratio of 4.726 (95 % CI 1.629-13.714) for CSS (P = 0.004). CISH revealed HER2 gene amplification in 3/10 tumours with ≥30 % micropapillary component. In conclusion, for BC treated with TUR-B and RCT, the presence of micropapillary morphology in more than 30 % of the tumour is an adverse prognostic factor. Further studies are needed to evaluate a potential benefit of different, especially multimodal treatment strategies for micropapillary UC and also other subtypes of UC. Her2 represents a promising therapeutic target in a subset of micropapillary UC. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|